Article Sidebar

PDF
Date Published: 08/07/2022
Online Published: 08/07/2022
Abstract Views: 84
Views PDF: 41
DOI: https://doi.org/10.55046/vjrnm.34.580.2019
Issue
No. 34 (2019)
Section
Scientific research
How to Cite
Le, N. H., Mai, H. S., Nguyen, T. N., Ngo, T. M. H., Hoang, Q. T., Tran, N. L., Nguyen, T. K. D., & Le, N. H. (2022). Relationships between BRAFV600E mutation, clinicopathologic factors and 18F-FDG avidity in radioiodine-refractory differentiated thyroid carcinoma patients. Vietnamese Journal of Radiology and Nuclear Medicine, 34, 61-67. https://doi.org/10.55046/vjrnm.34.580.2019

Relationships between BRAFV600E mutation, clinicopathologic factors and 18F-FDG avidity in radioiodine-refractory differentiated thyroid carcinoma patients

Le Ngoc Ha1, Mai Hong Son1, Nguyen Thi Nhung1, Ngo Thi Minh Hanh1, Hoang Quoc Truong2, Tran Ngoc Luong2, Nguyen Thi Kim Dung2, Le Ngoc Ha2,
1 Military Central Hospital 108
2 Endocrine central hospital

Main Article Content

Abstract

SUMMARY


Objectives: The BRAFV600E mutation is one of the prognostic factors in thyroid carcinoma related to GLUT-1 expression which increases 18F-FDG uptake. In this study, we investigated the relationship between BRAFV600E mutation, clinicopathologic factors and 18F-fluoro-2-deoxyglucose (18F-FDG) avidity in radioiodine-refractory differentiated thyroid carcinoma.
Methods: Total 46 radioiodine-refractory DTC patients who underwent BRAFV600E analysis from the biopsy and 18F-FDG positron emission
tomography/computed tomography from 2011 to 2018. Semi-quantitative analysis of highest hypermetabolic lesion was accessed by automated polygonal regions of interest (ROIs) drawing on attenuation-corrected PET images
the Workstation AW4.7(GE). The relationship between BRAF mutation, clinicopathologic factors, and 18F-fluoro-2-deoxyglucose (18F-FDG) avidity was investigated.
Results: Patients with the BRAFV600E mutation present higher 18F-FDG uptake (median of SUVmax: 7,11) than those without mutation
(median of SUVmax: 4,91) but the difference is not statisticcal significance (p=0,236). The tumor size (p = 0.006) and distant metastases (0,03) were significantly associated with 18F-FDG uptake in univariate analysis. Aggressive histopathologic type of DTC is only the factor (p = 0.01) related to FDG uptake significantly (p = 0.01) in both univariate and multivariate analysis.
Conclusion: The aggressive and classic type of DTC were the factors significantly related to 18F-FDG avidity in both univariate and multivariate
analysis. The effect BRAFV600E of mutation on glucose metabolism in radio iodine refractory patients needs further study in larger groups of patients.

Article Details

Keywords

18F-fluorodeoxyglucose, Positron-emission tomography, BRAFV600E mutation, histopathologic type, radioiodine refractory

References

TÀI LIỆU THAM KHẢO
1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.
2. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of clinical endocrinology and metabolism. 2006;91(8):2892-9.
3. Lee SH, Han S, Lee HS, Chae SY, Lee JJ, Song DE, et al. Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma. Nuclear medicine and molecular imaging. 2016;50(1):38-45.
4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
5. Yoon S, An Y-S, Lee SJ, So EY, Kim J-H, Chung Y-S, et al. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer. Medicine. 2015;94(48):e2063-e.
6. Yoon M, Jung SJ, Kim TH, Ha TK, Urm SH, Park JS, et al. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Endocrine research. 2016;41(1):64-9.
7. Ozderya A, Temizkan S, Gul AE, Ozugur S, Sargin M, Aydin K. Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in (18)F fluorodeoxyglucose positron emission tomography. Endocrine. 2017;55(1):215-22.
8. Santhanam P, Khthir R, Solnes LB, Ladenson PW. The relationships of BRAF(V600E) mutation status to FDG
PET/CT avidity in thyroid cancer: a review and meta-analysis. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2018;24(1):21-6.
9. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine- 131-iodide uptake in thyroid cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1996;37(9):1468-72.
10. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(17):3226-35.